share_log

愛帝宮:有關建議股份合併之經修訂時間表

AIDIGONG: REVISED TIMETABLE IN RELATION TOPROPOSED SHARE CONSOLIDATION

HKEX ·  Jul 5 09:02

Summary by Moomoo AI

愛帝宮母嬰健康股份有限公司(股份代號:286)宣布,原定於2024年7月3日發布的有關股份合併的通函因需要額外時間確認內容而延遲至7月10日發布。該通函將包含股份合併的進一步細節及股東特別大會的召開通知。股份合併預計於7月29日生效,當日也將開始以合併後的新股份進行交易。此外,公司將於7月25日召開股東特別大會,並於同日公布會議投票結果。公司主席王愛兒於2024年7月5日發出此公告。
愛帝宮母嬰健康股份有限公司(股份代號:286)宣布,原定於2024年7月3日發布的有關股份合併的通函因需要額外時間確認內容而延遲至7月10日發布。該通函將包含股份合併的進一步細節及股東特別大會的召開通知。股份合併預計於7月29日生效,當日也將開始以合併後的新股份進行交易。此外,公司將於7月25日召開股東特別大會,並於同日公布會議投票結果。公司主席王愛兒於2024年7月5日發出此公告。
Edigongmu Infant Health Co., Ltd. (Stock code: 286) announced that the letter regarding stock merger originally scheduled to be released on July 3, 2024 has been delayed to July 10 due to the need for additional time to confirm the content. The letter will contain further details on the stock merger and the notification of the shareholder's special meeting. The stock merger is expected to take effect on July 29, and trading will also begin on the same day with the new merged shares. In addition, the company will hold a special meeting of shareholders on July 25 and announce the voting results on the same day. The announcement was made by the company's chairman, Wang Aier, on July 5, 2024.
Edigongmu Infant Health Co., Ltd. (Stock code: 286) announced that the letter regarding stock merger originally scheduled to be released on July 3, 2024 has been delayed to July 10 due to the need for additional time to confirm the content. The letter will contain further details on the stock merger and the notification of the shareholder's special meeting. The stock merger is expected to take effect on July 29, and trading will also begin on the same day with the new merged shares. In addition, the company will hold a special meeting of shareholders on July 25 and announce the voting results on the same day. The announcement was made by the company's chairman, Wang Aier, on July 5, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more